VKTX

Viking Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · vikingtherapeutics.com

$30.00

Mkt Cap $3.4B

52w Low $22.96 34.9% of range 52w High $43.15

50d MA $33.53 200d MA $32.77

P/E (TTM) -9.4x

EV/EBITDA -9.7x

P/B 5.3x

Debt/Equity 0.0x

ROE -56.3%

P/FCF -14.2x

RSI (14) —

ATR (14) —

Beta 0.82

50d MA $33.53

200d MA $32.77

Avg Volume 2.6M

About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcohol…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 29, 2026	AMC	-1.01	-1.37	-35.6%	31.33	-2.7%	-0.5%	-4.2%	—	—	—	—	—
Feb 11, 2026	AMC	-0.89	-1.38	-55.1%	28.55	+18.2%	+6.8%	+1.6%	+6.7%	+5.6%	+8.9%	+24.8%	—
Oct 22, 2025	AMC	-0.70	-0.81	-15.7%	31.42	+12.8%	+8.0%	+9.5%	+14.4%	+11.2%	+12.1%	+9.0%	—
Jul 23, 2025	AMC	-0.44	-0.58	-31.8%	33.40	-5.7%	+0.3%	+3.1%	-0.6%	-1.5%	+0.9%	-22.2%	—
Apr 23, 2025	AMC	-0.34	-0.41	-20.6%	25.79	+1.2%	-0.5%	-3.1%	+0.6%	+8.3%	+11.9%	+4.6%	—
Feb 5, 2025	AMC	-0.28	-0.32	-14.3%	33.50	-7.4%	-6.1%	-2.8%	-9.9%	-10.6%	-12.5%	-13.1%	—
Oct 23, 2024	AMC	-0.24	-0.22	+8.3%	60.39	+8.9%	+21.2%	+29.2%	+23.4%	+21.5%	+18.8%	-12.9%	—
Jul 24, 2024	AMC	-0.26	-0.20	+23.1%	50.41	+17.0%	+28.3%	+30.9%	+21.5%	+12.1%	+13.1%	+28.2%	—
Apr 24, 2024	AMC	-0.27	-0.26	+3.7%	65.07	-3.2%	+5.8%	+14.2%	+15.9%	+22.3%	+17.5%	-3.6%	—
Feb 7, 2024	AMC	-0.25	-0.25	+0.0%	24.48	+5.2%	+18.0%	+24.9%	+29.6%	+25.0%	+31.7%	+193.2%	—
Oct 25, 2023	AMC	-0.22	-0.23	-4.5%	10.67	-15.7%	-9.4%	-13.4%	-10.2%	-8.1%	-10.3%	+15.1%	—
Jul 26, 2023	AMC	-0.21	-0.19	+9.5%	14.28	-4.7%	-4.0%	+1.1%	+1.5%	-0.8%	-2.6%	-4.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 30	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$31.33	$30.48	-2.7%	-0.5%	-4.2%	—	—	—
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.33	$32.34	+0.0%	+0.7%	-0.5%	+2.7%	+5.9%	+0.6%
Nov 12	Canaccord Genuity	Maintains	Buy → Buy	—	$40.60	$42.22	+4.0%	+0.4%	-3.9%	-3.7%	-5.9%	-7.0%
Oct 24	JP Morgan	Maintains	Overweight → Overweight	—	$33.92	$35.00	+3.2%	+1.5%	+5.9%	+3.0%	+3.8%	+12.5%
Oct 23	Morgan Stanley	Maintains	Overweight → Overweight	—	$31.42	$35.44	+12.8%	+8.0%	+9.5%	+14.4%	+11.2%	+12.1%
Sep 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.57	$25.55	-0.1%	+0.9%	+2.8%	+7.0%	+9.0%	+16.2%
Sep 22	BTIG	Maintains	Buy → Buy	—	$25.40	$25.35	-0.2%	+3.3%	-1.7%	+4.8%	-1.2%	+0.7%
Aug 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.09	$26.00	-38.2%	-42.1%	-39.0%	-39.0%	-38.2%	-38.6%
Jul 24	Raymond James	Maintains	Strong Buy → Strong Buy	—	$33.40	$31.50	-5.7%	+0.3%	+3.1%	-0.6%	-1.5%	+0.9%
Jul 24	Citigroup	Maintains	Neutral → Neutral	—	$33.40	$31.50	-5.7%	+0.3%	+3.1%	-0.6%	-1.5%	+0.9%
Jun 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.95	$27.11	+0.6%	+0.5%	+4.5%	-1.6%	-1.7%	-1.0%
Apr 28	Truist	Maintains	Buy → Buy	—	$24.99	$25.11	+0.5%	+3.8%	+11.8%	+15.5%	+14.5%	+17.5%
Apr 24	Morgan Stanley	Maintains	Overweight → Overweight	—	$25.79	$26.09	+1.2%	-0.5%	-3.1%	+0.6%	+8.3%	+11.9%
Apr 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.79	$26.09	+1.2%	-0.5%	-3.1%	+0.6%	+8.3%	+11.9%
Apr 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.60	$22.04	-6.6%	+1.4%	+0.5%	+8.0%	+9.3%	+8.7%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.98	$28.00	+0.1%	-5.9%	-6.6%	-8.3%	-13.7%	-14.5%
Mar 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.96	$26.26	-6.1%	-5.2%	+5.7%	+6.3%	+10.5%	+6.7%
Feb 7	B. Riley Securities	Maintains	Buy → Buy	—	$31.46	$31.40	-0.2%	+3.5%	-4.1%	-4.8%	-6.8%	-6.2%
Feb 7	Maxim Group	Maintains	Buy → Buy	—	$31.46	$31.40	-0.2%	+3.5%	-4.1%	-4.8%	-6.8%	-6.2%
Feb 6	Raymond James	Maintains	Strong Buy → Strong Buy	—	$33.50	$31.02	-7.4%	-6.1%	-2.8%	-9.9%	-10.6%	-12.5%
Feb 6	Piper Sandler	Maintains	Overweight → Overweight	—	$33.50	$31.02	-7.4%	-6.1%	-2.8%	-9.9%	-10.6%	-12.5%
Feb 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.50	$31.02	-7.4%	-6.1%	-2.8%	-9.9%	-10.6%	-12.5%
Jan 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$32.56	$32.94	+1.2%	+0.3%	+1.0%	+4.6%	+7.3%	+6.0%
Jan 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.60	$40.00	-1.5%	-3.2%	-4.2%	-16.4%	-14.1%	-19.8%
Jan 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.66	$41.52	-0.3%	-2.5%	-5.6%	-6.7%	-18.6%	-16.3%
Dec 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$41.49	$44.18	+6.5%	+1.8%	+2.0%	+2.1%	+2.9%	-0.8%
Dec 18	HC Wainwright & Co.	Maintains	Buy → Buy	—	$46.70	$43.09	-7.7%	-18.0%	-11.2%	-9.5%	-9.4%	-9.3%
Nov 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$53.42	$53.33	-0.2%	+2.0%	-0.9%	-3.6%	-5.9%	-4.1%
Nov 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.99	$55.27	+6.3%	+2.8%	+4.8%	+1.8%	-0.9%	-3.3%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$63.14	$63.53	+0.6%	+2.4%	+4.3%	+9.0%	+8.5%	-0.3%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$60.39	$65.75	+8.9%	+21.2%	+29.2%	+23.4%	+21.5%	+18.8%
Oct 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$66.68	$67.16	+0.7%	-6.1%	-6.3%	-1.3%	-1.3%	-1.9%
Sep 25	Oppenheimer	Maintains	Outperform → Outperform	—	$61.93	$62.69	+1.2%	+1.9%	+0.6%	-0.5%	+2.2%	+0.1%
Sep 12	Morgan Stanley	Maintains	Overweight → Overweight	—	$60.83	$62.71	+3.1%	+3.3%	+9.7%	+10.3%	+3.5%	+6.0%
Jul 25	Raymond James	Maintains	Strong Buy → Strong Buy	—	$50.41	$59.00	+17.0%	+28.3%	+30.9%	+21.5%	+12.1%	+13.1%
Jul 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.41	$59.00	+17.0%	+28.3%	+30.9%	+21.5%	+12.1%	+13.1%
Jun 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$52.74	$52.42	-0.6%	-1.2%	-9.4%	-10.1%	-3.7%	+0.5%
Jun 17	Truist	Maintains	Buy → Buy	—	$52.02	$51.61	-0.8%	+0.0%	-2.7%	-3.1%	+1.4%	+0.2%
Jun 4	Maxim Group	Maintains	Buy → Buy	—	$62.27	$65.00	+4.4%	-9.7%	-5.4%	-11.7%	-10.1%	-9.5%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$62.27	$65.00	+4.4%	-9.7%	-5.4%	-11.7%	-10.1%	-9.5%
May 16	Raymond James	Upgrade	Outperform → Strong Buy	—	$78.01	$76.26	-2.2%	-11.5%	-14.1%	-13.4%	-17.7%	-19.2%
May 16	Truist	Maintains	Buy → Buy	—	$78.01	$76.26	-2.2%	-11.5%	-14.1%	-13.4%	-17.7%	-19.2%
Apr 25	HC Wainwright & Co.	Maintains	Buy → Buy	—	$65.07	$63.00	-3.2%	+5.8%	+14.2%	+15.9%	+22.3%	+17.5%
Mar 27	Oppenheimer	Maintains	Outperform → Outperform	—	$80.83	$82.08	+1.5%	+3.1%	+1.4%	-1.6%	-4.3%	-3.0%
Mar 26	BTIG	Maintains	Buy → Buy	—	$69.19	$77.51	+12.0%	+16.8%	+20.5%	+18.5%	+14.9%	+11.8%
Mar 26	Oppenheimer	Maintains	Outperform → Outperform	—	$69.19	$77.51	+12.0%	+16.8%	+20.5%	+18.5%	+14.9%	+11.8%
Mar 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.19	$77.51	+12.0%	+16.8%	+20.5%	+18.5%	+14.9%	+11.8%
Mar 15	Stifel	Maintains	Buy → Buy	—	$65.05	$67.20	+3.3%	-3.8%	-2.6%	+0.2%	+9.2%	+8.5%
Mar 15	Maxim Group	Maintains	Buy → Buy	—	$65.05	$67.20	+3.3%	-3.8%	-2.6%	+0.2%	+9.2%	+8.5%
Mar 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$65.05	$67.20	+3.3%	-3.8%	-2.6%	+0.2%	+9.2%	+8.5%

Recent Filings

8-K · 1.02 !! High

Ligand Pharmaceuticals Incorporated -- 8-K 1.02: Material Agreement Terminated

The TR-Beta Program license termination with Valley Blvd effective May 4, 2026 removes a development partnership, though the filing doesn't specify whether this was mutual, breach-based, or regulatory-driven—investors should clarify the reason's impact on the company's pipeline.

Apr 30

8-K

Viking Therapeutics, Inc -- 8-K Filing

Unable to provide analysis: this 8-K contains only signature blocks without disclosed material events, transactions, or financial information necessary for investor guidance.

Feb 11

Data updated apr 27, 2026 7:49am · Source: massive.com